Evidence map›Paper›PMID 36931626›Full record

ArticleMolecular & cellular proteomics : MCP2023

PI3Kα Translocation Mediates Nuclear PtdIns(3,4,5)P

Michelle Palmieri, Bruno Catimel, Dmitri Mouradov, Anuratha Sakthianandeswaren, Eugene Kapp, Ching-Seng Ang, Nicholas A Williamson, Cameron J Nowell, Michael Christie, Jayesh Desai and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Michelle PalmieriPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.
Bruno CatimelPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.
Dmitri MouradovPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.
Anuratha SakthianandeswarenPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.
Eugene KappDepartment of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia; Advanced Technology and Biology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Ching-Seng AngBio21 Mass Spectrometry and Proteomics Facility, The University of Melbourne, Parkville, Victoria, Australia.
Nicholas A WilliamsonBio21 Mass Spectrometry and Proteomics Facility, The University of Melbourne, Parkville, Victoria, Australia.
Cameron J NowellDrug Discovery Biology, Monash Institute for Pharmaceutical Science, Parkville, Victoria, Australia.
Michael ChristiePersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Pathology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Jayesh DesaiDivision of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Peter GibbsPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia; Department of Medical Oncology, Western Health, Footscray, Victoria, Australia.
Antony W BurgessPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia; Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia.
Oliver M SieberPersonalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia; Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia; Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia. Electronic address: sieber.o@wehi.edu.au.
Walter and Eliza Hall Institute of Medical Research · AUThe University of Melbourne · AUDiscovery Institute · USPeter MacCallum Cancer Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The canonical view of PI3Kα signaling describes phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P

Indexed as

Colorectal NeoplasmsPhosphatidylinositolsCell NucleusHumansPhosphatidylinositol PhosphatesSignal TransductionPhosphatidylinositol PhosphatesPhosphatidylinositolscolorectal cancernuclear import pathwayPI3Kαpre-mRNA splicingPtdIns(3,4,5)P(3) interactome

Identifiers

PMID36931626
PMCPMC10130476
OpenAlexW4324334086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.